Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.

Nicholas ReboldSara AlosaimyJeffrey C PearsonBrandon DionneAhmad TaqiAbdalhamid LagnfKristen LucasMark BiagiNicholas LombardoJoshua EudyDaniel T AndersonMonica V MahoneyWesley D KufelJoseph A D'AntonioBruce M JonesJeremy J FrensTyler BaumeisterMatthew GeriakGeorge SakoulasDimitrios FarmakiotisDino DelaportasJeremy LarewMichael P VeveMichael J Rybak

Published in: Infectious diseases and therapy (2024)

Dalbavancin may serve as a useful tool in facilitating hospital discharge in patients with Gram-positive BSI. Randomized controlled trials are anticipated to validate dalbavancin as a surrogate to current treatment standards.

Keyphrases

gram negative
multidrug resistant
randomized controlled trial
cross sectional
clinical trial
combination therapy
systematic review
escherichia coli
study protocol